Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound for modulating c-Kit activity according to Formula I,

1

or a pharmaceutically acceptable salt, thereof, wherein,

ring A is:

(R ¹) ₀₋₄	(R ¹) ₀₋₃	Z
Z	$ \begin{array}{c} Z \\ \hline $	N Z N $(R^1)_{0-1}$
(R ¹) ₀₋₁	Z	Z N II (R ¹) ₀₋₁
(R ¹) ₀₋₄	$(R^1)_{0-5}$ Z Z Y Y	(R ¹) ₀₋₅ , Y , Z , Z ,

$$(R^{1})_{0-6} \xrightarrow{Y} (R^{1})_{0-6} \xrightarrow{Y} (R^{1})_{0-6} \xrightarrow{Y} Y$$

wherein each Y is independently either =C(H)- or =N-; and Z is selected from -O-, -S-, and $-N(R^7)$ -;

- each R^1 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl C_{1-6} alkyl;
- two adjacent of R¹, together with the annular atoms to which they are attached, can form a fiveto six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R¹⁰;

L¹ is a single bond;

ring B is phenyl a five to ten-membered aryl or a five-to ten-membered heterocyclyl;

- each R^2 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- two adjacent of R², together with the annular atoms to which they are attached, can form a fiveto six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R¹⁵;
- L^2 is selected from -N(H)N(H)C(=O)N(H)-, -CH₂N(H)C(=O)N(H)-, -CH₂OC(=O)N(H)-, and -XCH₂C(=O)N(H)-; wherein X is selected from -O-, -S(O)₀₋₂-, and -N(R⁷)-; and any C-H

of L² is optionally C-R²⁰;

ring C is phenyl or pyridyl;

each R³ is independently selected from halogen, trihalomethyl, -CN,

-NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; provided R^3 is not a cyclic sulfonamide attached to ring C via the nitrogen of said cyclic sulfonamide,


wherein there exists at least one of R³ that is halogen or trihalomethyl;

- two adjacent of R³, together with the annular atoms to which they are attached, can form a fiveto-six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R²⁵;
- R^4 is selected from -H, optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl;
- two of R⁴, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- R^5 is selected from -H, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -CO₂R⁴, optionally substituted C₁₋₆alkyl, optionally substituted C₁₋₆alkenyl, and optionally substituted C₁₋₆alkynyl;
- R^7 is selected from -H, optionally substituted $C_{1\text{-}6}$ alkyl, -SO₂N(R^4) R^4 , -CO₂ R^4 , -C(=O)N(R^4) R^4 , -C(=N R^5)N(R^4) R^4 , -C(=N R^5) R^4 , -C(=O) R^4 , optionally substituted alkoxy, optionally substituted aryl $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl; and

each of R^{10} , each of R^{15} , each of R^{20} , and each of R^{25} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;

provided:

- 1) when both ring B and ring C are phenyl:
 - a) and the compound comprises ring B-CH₂N(H)C(=O)N(H)-ring C, then L¹ must be a single bond; R³ can not comprise a group of the formula -O(CH₂)₂₋₄-N-piperazine that is *ortho* to L²; and ring A cannot be a 5-methyl-[1,2,4]-oxadiazol-3-yl radical, a 4H-[1,2,4]-oxadiazol-5-one-3-yl radical, nor a 4'-[2,2';6',2"]terpyridinyl radical;
 - b) and L¹ is single bond, then L² cannot comprise -N(H)C(=O)C(=O)N(H)- nor -N(H)C(=Q)C(H)CNC(=O)- (where Q is S or O);
 - c) and L¹ is other than single bond, then A cannot be quinolin-2-yl-L¹, quinolin-3-yl-L¹, or quinolin-4-yl-L¹;
- 2) when ring A is a fused aryl system, then L¹-must be a single bond;
- 3) when ring B is phenyl, ring-C-is a C₆₋₁₆carbocyclic, L¹ is a single-bond, and the compound comprises ring-B-OCH₂C(=O)N(H) then ring A cannot be a 2,5-dimethyl-1H-pyrrole-1-yl radical;
- 4) ring A cannot be a pyrimidin 2 yl radical when L⁴ is N(H) and ring B is phenyl;
- 5) when the compound comprises the formula,



where V is -C(H) or -N, and there is a nitrogen of L^2 bound directly to ring B, then A can not comprise a [1,2,4] oxadiazol 3-yl radical; and

N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1of: compound 6) the is not one N-[4-(phenyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(2,3-dimethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenylloxy}acetamide, N-(2,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(2,6-dimethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-(2,4,6yl)phenylloxy}acetamide, N-(2-ethylphenyl)-2-{[3-(1H-tetrazol-1trimethylphenyl)acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, yl)phenylloxy}acetamide, N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[2-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, yl)phenylloxy}acetamide, N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(4-chloro-3-methylphenyl)-2-{[3-(1H-tetrazol-1-N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, $2-\{[3-(1H-tetrazol-1-yl)phenyl]oxy\}-N-[2$ yl)phenyl]oxy}acetamide, (trifluoromethyl)phenyl]acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-[3-4-[({[3-(1H-tetrazol-1-(trifluoromethyl)phenyl]acetamide, methyl yl)phenylloxy}acetyl)aminolbenzoate, ethyl 4-[({[3-(1H-tetrazol-1yl)phenyl]oxy}acetyl)amino]benzoate, $3-[({[3-(1H-tetrazol-1-yl)phenyl]}$ oxy}acetyl)amino]benzoic acid, N-[3-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[2-chloro-5-(trifluoromethyl) phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide, N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, and N-(4-acetylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide.

2-12. (cancelled)

- 13. (original) The compound according to claim $\frac{10}{1}$, wherein there exists at least one of \mathbb{R}^3 that is trifluoromethyl.
- 14. (original) The compound according to claim 13, wherein ring C is a phenyl comprising a trifluoromethyl radical meta- to L^2 .
- 15. (currently amended) The compound according to claim 10, wherein each of R^3 is independently selected from halogen, trihalomethyl, $-OR^4$, $-C(=O)R^4$, and optionally substituted C_{1-6} alkyl.
- 16. (currently amended) A compound for modulating c-Kit activity according to the following Formula: H,

$$(R^{26})_{0.4}$$
 $(R^{30})_{1.5}$
 $(R^{30})_{1.5}$

$$(R^{26})_{0.4}$$
 E^{-G}
 N
 $(R^{30})_{1.5}$

11

or a pharmaceutically acceptable salt, thereof, wherein,

W is selected from the following:

(R ²⁷) ₀₋₄	(R ²⁷) ₀₋₃	$(R^{27})_{0-3}$
Z	$Z = \frac{1}{11}$ $N - V - N$ $(R^{27})_{0-2}$	(R ²⁷) ₀₋₁
(R ²⁷) ₀₋₁	Z	Z N
(R ²⁷) ₀₋₄ Y—Y	(R ²⁷) ₀₋₅	(R ²⁷) ₀₋₅ Y Y Z Z
(R ²⁷) ₀₋₆ Y Y Y Y	$(\mathbb{R}^{27})_{0-6}$	$(R^{27})_{0-6} \xrightarrow{\stackrel{Y}{{}{}{}}} \begin{pmatrix} Y & Y & Y & Y & Y & Y & Y & Y & Y & Y$

each of R^{27} independently selected from halogen, trihalomethyl, -CN, -NO₂, -OR⁵⁵, -S(O)₀₋₂R⁵⁵, -SO₂N(R⁵⁵)R⁵⁵, -C(=O)N(R⁵⁵)R⁵⁵, -C(=NR⁵⁰)N(R⁵⁵)R⁵⁵, -C(=NR⁵⁰)R⁵⁵, -N(R⁵⁵)SO₂R⁵⁵, -N(R⁵⁵)C(O)R⁵⁵, -NCO₂R⁵⁵, -C(=O)R⁵⁵, optionally substituted alkoxy, optionally substituted C₁-

₆alkyl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;

each Y is independently either =C(H)- or =N-;

Z is selected from -O-, -S(O) $_{0-2}$ -, and -N(R 7)-

E and G are each independently selected from -O-, -S(O) $_{0-2}$ -, -C(R 31)R 32 -, and -N(R 33)-;

 J_1 and J_2 are each independently = C(H)- or = N-;

- R^{26} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -CO₂R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- R^{30} is independently selected from halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)R⁴⁰, -N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl, wherein there exists at least one of R^{30} that is trihalomethyl; Θ F
- two adjacent of R²⁶ or two adjacent of R³⁰, together with the annular atoms to which they are attached, can form a five to six membered ring containing up to two heteroatoms and optionally substituted with up to three of R³⁵;
- $R^{31} and \ R^{32}$ are each independently selected from -H, halogen, trihalomethyl, -CN, -NO2, -OR $^{40},$ -N(R $^{40})R^{40},$ -S(O)0-2R $^{40},$ -SO2N(R $^{40})R^{40},$ -CO2R $^{40},$ -C(=O)N(R $^{40})R^{40},$ -C(=NR $^{50})N(R^{40})R^{40},$ -C(=NR $^{50})R^{40},$ -N(R $^{40})SO_2R^{40},$ -N(R $^{40})C(O)R^{40},$ -NCO2R $^{40},$ -C(=O)R $^{40},$ optionally substituted alkoxy, optionally substituted C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl;

- R^{33} is selected from -H, optionally substituted lower alkyl, $-SO_2N(R^{40})R^{40}$, $-CO_2R^{40}$, $-C(=O)N(R^{40})R^{40}$, $-C(=NR^{50})N(R^{40})R^{40}$, $-C(=NR^{50})R^{40}$, $-C(=O)R^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- R^{40} is selected from -H, optionally substituted alkoxy, optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted aryl, optionally substituted aryl $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl;
- two of R⁴⁰, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- R^{50} is selected from -H, -CN, -NO₂, -OR⁴⁰, -S(O)₀₋₂R⁴⁰, -CO₂R⁴⁰, optionally substituted C₁₋₆alkynyl; and optionally substituted C₁₋₆alkynyl;
- R^{55} is selected from -H, optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl; and
- two of R⁵⁵, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P.

17. (cancelled)

18. (currently amended) The compound according to claim $47 \ \underline{16}$, wherein R^{30} is selected from halogen, trihalomethyl, $-OR^{40}$, $-N(R^{40})R^{40}$, $-C(=O)R^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl, wherein there exists at least one of R^{30} that is trifluoromethyl.

- 19. (cancelled)
- 20. (cancelled)
- 21. (cancelled)
- 22. (currently amended) The compound according to claim 21 16, wherein W is selected from the

following:

$(R^{27})_{0-4}$	(R ²⁷) ₀₋₃	$(\mathbb{R}^{27})_{0-3}$
N-\ (R ²⁷) ₀₋₁	$Z \frac{1}{\ \cdot \ } $ $(R^{27})_{0-2}$	$(R^{27})_{0-1}$
$(R^{27})_{0-1}$	Z	N
(R ²⁷) ₀₋₄	(R ²⁷) ₀₋₅ Y Z	$(R^{27})_{0-5}$
(R ²⁷) ₀₋₆ Y Y Y	(R ²⁷) ₀₋₆ Y Y	$(R^{27})_{0-6}$ Y Y Y Y Y

and R²⁷ is defined as above.

23. (withdrawn from consideration) The compound according to claim 22, wherein E is selected from -O-, -S(O) $_{0-2}$ -, and -NH-; and G is -CH $_{2}$ -.

- 24. (withdrawn from consideration) The compound according to claim 22, wherein E is either $-CH_2$ or -NH-; and G is selected from -O-, -S-, and -NH-.
- 25. (cancelled)
- 26. (cancelled)
- 27. (currently amended) The compound according to claim 1, selected from Table 3:

 A compound selected from the following Table:

	Table 3		
Entry	Name	Structure	
1	N-[5-chloro-2-(methyloxy)phenyl]-2-{[3- (1H-tetrazol-1-yl)phenyl]oxy}acetamide	O H O D D D D D D D D D D D D D D D D D	
2	N-phenyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N-N N-N N-N	
3	N-(2-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N-N-N H ₃ C	

Table 3		
Entry	Name	Structure
4	N-(2-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N N CI
5	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N
6	ethyl 2-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate	N.N.N
7	N-(3-chloro-2-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N CH ₃ CI
8	N-(3-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N=N-N N=N-N N=N-N N=N-N N=N-N N-N N-N N-

	Table 3		
Entry	Name	Structure	
9	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2H-tetrazol-5- yl)phenyl]oxy}acetamide	N N CI	
10	N-(4-chloro-2-fluorophenyl)-2-{[3-(1H- tetrazol-1-yl)phenyl]oxy}acetamide	N. N. N. P. P. CI	
11	N-(4-bromo-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N.N.N. O.N. CH3	
12	N-(4-morpholin 4-ylphenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N. N. O. N. N. N. O. N.	
13	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N-N-N-P-F-F	

	Table 3		
Entry	Name	Structure	
14	N-[4-bromo-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N. N. H. F. F.	
15	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	O N F F F F F F F F F F F F F F F F F F	
16	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	N = N CI	
17	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(5-methyl-1H-tetrazol-1- yl)phenyl]oxy}acetamide	N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-	
18	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-methyl-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CH ₃ H F CI	

	Table 3		
Entry	Name	Structure	
19	N-(4-chlorophenyl)-N-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N O O CH ₃	
20	N-[4-chloro-2-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide		
21	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2,5-dioxopyrrolidin-1- yl)phenyl]oxy}acetamide		
22	(2E)-N-[4-chloro-3- (trifluoromethyl)phenyl]-3-[3-(1H-tetrazol- 1-yl)phenyl]prop-2-enamide	N N E N CI	
23	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N.N.N. F FFF	

1.000	Table 3		
Entry	Name	Structure	
24	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2-methyl-2H-tetrazol-5- yl)phenyl]oxy}acetamide	H ₃ C F F	
25	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,4-dichloro-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CI CI CI FF F	
26	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]thio}acetamide	N. N. N. S. N. H. F. F. F.	
27	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	N-N-N-N-FEFF	
28	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-(1H-tetrazol-1- yl)phenyl]oxy}acetamide		

	Table 3		
Entry	Name	Structure	
29	methyl 1-{3-[(2-{[4-chloro-3- (trifluoromethyl)phenyl]amino}-2- oxoethyl)oxy]phenyl}-1H-1,2,3-triazole-4- carboxylate	H ₃ C ₀ O _{N-N-N} CI N _{N-N} CI F _F F _F	
30	1,1-dimethylethyl {4 [({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]phenyl}carba mate	N=N O N N	
31	1,1-dimethylethyl {4-[({[4-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]phenyl}earba mate	N.N. CONTRACTOR	
32	N-{4-[(1-ethylpiperidin-4-yl)amino]phenyl}-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N=N O NH	
33	N-{4-[(1-ethylpiperidin-3-yl)amino]phenyl}-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N CH ₃	

	Table 3		
Entry	Name	Structure	
34	N-(4-aminophenyl)-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N. N	
35	N-{4-[(1-ethylpiperidin-4- yl)amino]phenyl}-2-{[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	H ₃ C N H	
36	N-{4-[(1-ethylpiperidin-3- yl)amino]phenyl}-2-{[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CH ₃	
37	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-4-ylphenyl)oxy]acetamide	N CI F F	
38	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-methyl-N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	CI N.N.N.N.	

Table 3		
Entry	Name	Structure
39	N-1,3-benzothiazol-2-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N NH NzN.
40	N-quinolin-8-yl-2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	OHO N-N'N
41	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	ON-N.N.
42	N-isoquinolin-5-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	ON ON N-N'N
43	N-{3-[(phenylmethyl)oxy]phenyl}-2-{[3- (1H-tetrazol-1-yl)phenyl]oxy}acetamide	O N. Z.

Table 3		
Entry	Name	Structure
44	N-[5-methyl-2 (methyloxy)phenyl]-2-{[3- (1H-tetrazol-1-yl)phenyl]oxy}acetamide	H ₃ C NH NNN N
45	N-[2,5-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	H ₃ C. O CH ₃ NH NH N-N
46	N-(6-fluoro-1,3-benzothiazol-2-yl)-2-{[3- (1H-tetrazol-1-yl)phenyl]oxy}acetamide	F N N N N N N N N N N N N N N N N N N N
47	methyl-3-[({[3-(1H-tetrazol-1- yl)phenyl]oxy}acetyl)amino]benzoate	H³C.OLO
48	5-chloro-2-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]benzamide	N-N-N H ₂ N CI

Table 3		
Entry	Name	Structure
49	N-[5-chloro-2,4-bis(methyloxy)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N.N. N. O. CH3
50	N-[2-(phenyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	OH OH N-N'
51	N-[3-(aminosulfonyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	O'S'O
52	N-[2-(methyloxy)-5- (trifluoromethyl)phenyl]-2-{[3-(1H- tetrazol-1-yl)phenyl]oxy}acetamide	N, N, N CH3
53	N-(4-{[(4- methylphenyl)sulfonyl]amino}phenyl) 2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	Ozszo N N H

Table 3		
Entry	Name	Structure
54	N-(5-phenyl-1H-pyrazol-3-yl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	ON O N-N'N
55	N-1,3-benzothiazol-2-yl-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N NH
56	N-quinolin-8-yl-2-{[4-(1H-tetrazol-1- yl)phonyl]oxy}acetamide	
57	1,1-dimethylethyl 2-{3-[(2-{[4-chloro-3- (trifluoromethyl)phenyl]amino}-2- oxoethyl)oxy]phenyl}-1H-pyrrole-1- carboxylate	LOLO NATE F
58	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-pyrrol-2-yl)phenyl]oxy}acetamide	O N F F

	Table 3		
Entry	Name	Structure	
59	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyrimidin-5-ylphenyl)oxy]acetamide	N CI F F F F	
60	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	N. N. P. F.	
61	4-chloro-N-(2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}ethyl)-3- (trifluoromethyl)aniline	N. N. N. P. F.	
62	N-[4-chloro-3-(trifluoromethyl)phenyl]-N- (2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}ethyl)formamide	N.N.N.O.N.F.F.	
63	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-3-ylphenyl)oxy]acetamide	O P F F	

***************************************	Table 3		
Entry	Name	Structure	
64	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-furan-3-ylphenyl)oxy]acetamide	O N F F F	
65	(2E)-N-[4-fluoro-3- (trifluoromethyl)phenyl]-3-[3-(1H-tetrazol- 1-yl)phenyl]prop-2-enamide	N=N O F F	
66	N-[4-fluoro-3-(trifluoromethyl)phenyl]-3- [3-(1H-tetrazol-1-yl)phenyl]propanamide	N=N O F F	
67	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[6-(1H-tetrazol-1-yl)pyrimidin-4- yl]oxy}acetamide	N F F CI	
68	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(3,5-dimethylisoxazol-4- yl)phenyl]oxy}acetamide	H_3C CH_3 $N-O$	

Table 3		
Entry	Name	Structure
69	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-quinolin-7-ylphenyl)oxy]acetamide	CI F F
70	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-furan-2-ylphenyl)oxy]acetamide	ON H F F
71	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	N. N. H. H. F.
72	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-dibenzo[b,d]furan-4- ylphenyl)oxy]acetamide	F F CI
73	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	N CI

Table 3		
Entry	Name	Structure
74	N-methyl-N-[4-(methyloxy)phenyl]-2-{[3- (1H-tetrazol-1-yl)phenyl]oxy}acetamide	N O CH ₃
75	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-tetrazol-1-yl)phenyl]methyl}urea	N N CI FFF
76	N-[4-chloro-3-(trifluoromethyl)phenyl]-N-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	NN=N CI FFF
77	N-[4-fluoro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	N=N H O FFF
78	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[3-(pyridin-2- ylamino)phenyl]oxy}acetamide	F F F F F F F F F F F F F F F F F F F

Table 3		
Entry	Name	Structure
79	N-[2-fluoro-5-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	N, N
80	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	O N F F F
81	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyrimidin-5-ylphenyl)methyl]urea	N CI F F F
82	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyrimidin-5-ylphenyl)methyl]urea	CC FF
83	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	N H H F F F

Table 3		
Entry	Name	Structure
84	[3-(1H-tetrazol-1-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	N. N. N. P. F.
85	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	N F F F
86	N~2~-[4-chloro-3- (trifluoromethyl)phenyl]-N-[3-(1H- tetrazol-1-yl)phenyl]glycinamide	N. N. N. H. N. P. F. F. F.
87	2-{[4-chloro-3- (trifluoromethyl)phenyl]oxy}-N-[3-(1H- tetrazol-1-yl)phenyl]acetamide	N. N. H. O. F. F.
88	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-methyl-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	H ₃ C CI F F

Table 3		
Entry	Name	Structure
89	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	O N F F F
90	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F O N F F F
91	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	
92	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- 3-(1H-tetrazol-1-yl)benzenesulfonamide	N. N. N. S. N. H. F. F. F.
93	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- N-methyl-3-(1H-tetrazol-1- yl)benzenesulfonamide	N O O O O F F F F

Table 3		
Entry	Name	Structure
94	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	O NH F F
95	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide	H ₃ C ₂ O ₁ O ₁ O ₁ O ₂ O ₁ O ₂ O ₁ O ₂ O ₂ O ₃ O ₄ O ₄ O ₅
96	2-({4-[2,4-bis(methyloxy)pyrimidin-5- yl]phenyl}oxy)-N-[4-chloro-3- (trifluoromethyl)phenyl]acetamide	H ₃ C. O N F F
97	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-4-ylphenyl)oxy]acetamide	O N F F
98	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(methyloxy)-4-(1H-tetrazol-1- yl)phenyl]glycinamide	H ₃ C N H CI F F F

	Table 3		
Entry	Name	Structure	
99	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(methyloxy)-3-(1H-tetrazol-1- yl)phenyl]glycinamide	N N N H P F F F	
100	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(1H-tetrazol-1- yl)phenyl]glycinamide	H N F F	
101	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (2,3,5,6-tetrafluoro-4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	F F F F	
102	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-tetrazol-1-yl)phenyl]methyl}urea	ON H F F	
103	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	N H H F F	

Table 3		
Entry	Name	Structure
104	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-3-ylphenyl)methyl]urea	N N N F F
105	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- methyl-2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	N. N. N. O. N. F. F. F.
106	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	O CH ₃
107	N-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₃ C ₁ O _N NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
108	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H ₃ C·O N O CI F F F F

Table 3		
Entry	Name	Structure
109	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C ^{-O} N N N N N N N N N N N N N N N N N N N
110	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H ₃ C. ₀ N N N N N N N N N N N N N N N N N N N
111	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C. _O
112	1,1-dimethylethyl 2-{4-[(2-{[4-chloro-3- (trifluoromethyl)phenyl]amino}-2- oxoethyl)oxy]phenyl}-1H-indole-1- carboxylate	O I N CI FF
113	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- 4-(1H-tetrazol-1-yl)benzenesulfonamide	O, O O N CI S, N N N F F

Table 3		
Entry	Name	Structure
114	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(2H-tetrazol-5- yl)phenyl]glycinamide	HN. N=N
115	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,6-difluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F O N F F F
116	(3-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	O N F F
117	(3-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	N CI F F F
118	(3-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI F F F

Table 3		
Entry	Name	Structure
119	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [4-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	N N N N F F
120	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-3- ylphenyl)hydrazinecarboxamide	H. N. N. N. F. F. F.
121	(4-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	O N F F F
122	(4-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	O N F F
123	(4-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	ON FFFF

	Table 3		
Entry	Name	Structure	
124	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-4-ylphenyl)methyl]urea	N N N F F	
125	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-3- ylphenyl)hydrazinecarboxamide	N N N F F	
126	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyrimidin-5- ylphenyl)hydrazinecarboxamide	CI F F	
127	N-[5-chloro-2,4-bis(methyloxy)phenyl]-N'- [(4-pyrimidin-5-ylphenyl)methyl]urea	N CH3	
128	N-[5-chloro-2,4-bis(methyloxy)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	N CH ₃	

	Table 3		
Entry	Name	Structure	
129	(4-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate	N C C C C C C C C C C C C C C C C C C C	
130	(4-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	ON HOCH3	
131	1-(4-pyridin-3-ylphenyl)ethyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	CH ₃ O CI F F F	
132	1-(4-pyrimidin-5-ylphenyl)ethyl [4-chloro- 3-(trifluoromethyl)phenyl]carbamate	CH ₃ O CI F F F	
133	N-[5-chloro-2,4-bis(methyloxy)phenyl]-N'- [(3-pyridin-3-ylphenyl)methyl]urea	N O CH3	

Table 3		
Entry	Name	Structure
134	N-[5-chloro-2,4-bis(methyloxy)phenyl]-N'- [(3-pyrimidin-5-ylphenyl)methyl]urea	N N N CH ₃
135	(3-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	N O N O CH3
136	(3-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate	ON CH3
137	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- methyl-2-(3-pyrimidin-5- ylphenyl)hydrazinecarboxamide	CH ₃ O F F
138	N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	NH NH F

Table 3		
Entry	Name	Structure
139	N-{[3-(6-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N CI F F F
140	N-{[4-(6-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N N
141	N-{[3-(2-aminopyrimidin-5-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N N CI F F F
142	N-{[4-(2-aminopyrimidin-5-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	N N N F F
143	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyridin-3-ylphenyl)ethyl]urea	CH ₃ O CI N N F F

	Table 3		
Entry	Name	Structure	
144	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyrimidin-5-ylphenyl)ethyl]urea	CH ₃ O CI F F F	
145	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-indol-2-yl)phenyl]oxy}acetamide	O N F F F F F F F F F F F F F F F F F F	
146	N-[4-chloro-3 (trifluoromethyl)phenyl]-2- (isoquinolin-7-yloxy)acetamide	H F F CI	
147	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-4- ylphenyl)hydrazinecarboxamide	CC F F F	
148	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-4- ylphenyl)hydrazinecarboxamide	H N H F F	

Table 3		
Entry	Name	Structure
149	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-4-ylphenyl)methyl]urea	N N N F F
150	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-quinoxalin-6-ylphenyl)methyl]urea	N N N N N N N N N N N N N N N N N N N
151	methyl 3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazine-2- carboxylate	CH ₃ O H ₂ N N N N N N N N N F F
152	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-quinoxalin-6-ylphenyl)methyl]urea	O P F F
153	N-{[3-(2-amino-5-methylpyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CH ₃ NH ₂ NH ₂ NH ₂ NF F

	Table 3		
Entry	Name	Structure	
154	methyl 3-amino-6-(4-{[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazine-2- carboxylate	H ₂ C ₁ O N N N N N N N N N N N N N N N N N N N	
155	[3-(1H-tetrazol-1-yl)phenyl]methyl [3-chloro-4-(methyloxy)phenyl]carbamate	N=N O H CI	
156	N-[3-chloro-4-(methyloxy)phenyl]-N'-{[3- (1H-tetrazol-1-yl)phenyl]methyl}urea	N=N CI O-CH ₃	
157	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(5-hydroxy-1H-tetrazol-1- yl)phenyl]oxy}acetamide	HO N F F	
158	N-{[3-(2-amino-5-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI NH2 O FFFF	

Table 3		
Entry	Name	Structure
159	N-{[4-(2-amino-5-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI NH ₂
160	N-{[3-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI F F
161	N-{[4-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI C
162	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(pyrimidin-2- yloxy)phenyl]methyl}urea	F F
163	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- 3-(1H-tetrazol-1-yl)benzamide	N.N.N. P.F. F.F.

	Table 3		
Entry	Name	Structure	
164	3-amino-6-(3-{[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)-N-[2- (dimethylamino)ethyl]pyrazine-2- carboxamide	F F CI HN O HN O	
165	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-fluoropyridin-3- yl)phenyl]methyl}urea	F N N N F F F	
166	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea		
167	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-fluoropyridin-3- yl)phenyl]methyl}urea	P P P P P P P P P P P P P P P P P P P	
168	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	P CI F F CH ₃	

Table 3		
Entry	Name	Structure
169	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-methylpyridin-3- yl)phenyl]methyl}urea	H ₃ C N CF ₃
170	N-{[4-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	F NH ₂ CF ₃
171	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-methylpyridin-3- yl)phenyl]methyl}urea	H ₃ C N CI F F F
172	N-{[4-(2-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	N NH ₂
173	N-{[3-(2-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	NH ₂ NH ₂ CI F F F

	Table 3		
Entry	Name	Structure	
174	[3-(6-methylpyridin-3-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	H ₃ C CI F F	
175	[3-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	F CI F F F	
176	[3-(2-aminopyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	NH ₂ CI F F F	
177	(3-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N O N F F F	
178	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[6-(hydroxymethyl)pyridin-3- yl]phenyl}methyl)urea	HO CF ₃	

	Table 3		
Entry	Name	Structure	
179	N-{[3-(6-acetylpyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₃ C CF ₃	
180	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-cyanopyridin-3- yl)phenyl]methyl}urea	CN N CF ₃	
181	1,1-dimethylethyl (3S)-3-({[3-amino-6-(3- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	H ₂ N N N HN O	
182	3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)-N-[(3S)-piperidin-3-yl]pyrazine-2-carboxamide	HN E CI HN O HN O	

Table 3		
Entry	Name	Structure
183	1,1-dimethylethyl (3S)-3-({[3-amino-6-(4- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	O O O O O O O O O O O O O O O O O O O
184	3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)-N-[(3S)-piperidin-3-yl]pyrazine-2-carboxamide	F F F CI NH ON NH
185	[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H N N N N N N N N N N N N N N N N N N N
186	N-{[3-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	NH ₂ O CI F F F

Table 3		
Entry	Name	Structure
187	[6-(1H-tetrazol-1-yl)pyridin-2-yl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N O N F F
188	[3-(1H-benzimidazol-2-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N O N F F F F
189	[3-(6-amino-2-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₂ N CI CI F F F
190	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-3- yl]phenyl}methyl)urea	S CH ₃ CF ₃
191	[4-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₃ C N

Table 3		
Entry	Name	Structure
192	[4-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	F N NH ₂
. 193	[4-(2-aminopyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O N F F F F
194	(4-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	O N F F F
195	[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN P F F F
196	[4-(6-amino-2-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₂ N CH ₃

Table 3		
Entry	Name	Structure
197	[3-(1H-tetrazol-1-yl)phenyl]methyl 1,3- benzothiazol-2-ylcarbamate	N O N S
198	[3-(1H-tetrazol-1-yl)phenyl]methyl (5- bromopyridin-2-yl)carbamate	N Br
199	(3-pyridin-3-ylphenyl)methyl (3,5- dimethylphenyl)carbamate	CH ₃
200	(3-pyridin-3-ylphenyl)methyl [5-chloro-2- (methyloxy)phenyl]carbamate	CH ₃
201	[4-(1H-tetrazol-1-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	NN=N CI F F F

Table 3		
Entry	Name	Structure
202	(3-pyrimidin-5-ylphenyl)methyl [5-chloro- 2-(methyloxy)phenyl]carbamate	DE CO-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-
203	(4-pyrimidin-5-ylphenyl)methyl (3,4- dimethylphenyl)carbamate	ON CH3
204	(3-pyridin-3-ylphenyl)methyl (3,4- dimethylphenyl)carbamate	ON CH3
205	1,1-dimethylethyl 3-({[3-amino-6-(3- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	F F CI HN O HN O HN O N N N N N N N N N N N N N N N N N N

Table 3		
Entry	Name	Structure
206	1,1-dimethylethyl 3-({[3-amino-6-(4- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	F F F CI HN O HN O H ₂ N N
207	3-amino-6-(3-{[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)-N-piperidin-3- ylpyrazine-2-carboxamide	HN CI HN O HN O HN O
208	3-amino-6-(4-{[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)-N-piperidin-3- ylpyrazine-2-carboxamide	F F CI NH O H ₂ N N
209	1,1-dimethylethyl 4-{[3-amino-6-(3- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}piperazine-1-carboxylate	CI F F F NH NH NH NH

	Table 3		
Entry	Name	Structure	
210	1,1-dimethylethyl 4-{[3-amino-6-(4- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}piperazine-1-carboxylate	F F CI NH HN O NN	
211	N-({3-[5-amino-6-(piperazin-1-ylcarbonyl)pyrazin-2-yl]phenyl}methyl)- N'-[4-chloro-3- (trifluoromethyl)phenyl]urea	H ₂ N N HN O	
212	N-({4-[5-amino-6-(piperazin-1-ylcarbonyl)pyrazin-2-yl]phenyl}methyl)- N'-[4-chloro-3- (trifluoromethyl)phenyl]urea	H NH HN O	
213	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-pyrazol-4-yl)phenyl]methyl}urea	N.H. CF ₃	

Table 3		
Entry	Name	Structure
214	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-pyrazol-4-yl)phenyl]methyl}urea	HN CF ₃
215	[3-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN N N CF ₃
216	[4-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CF ₃ CI
217	N-{[3-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	N CI CF ₃
218	N-{[4-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N CF3

Table 3		
Entry	Name	Structure
219	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(2-fluoropyridin-3- yl)phenyl]methyl}urea	N F O CF ₃
220	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(2-fluoropyridin-3- yl)phenyl]methyl}urea	D CI CF ₃
221	[3-(1H-tetrazol-1-yl)phenyl]methyl [3- (trifluoromethyl)phenyl]carbamate	N.N.N.
222	[3-(1H-tetrazol-1-yl)phenyl]methyl [6- (trifluoromethyl)pyridin-2-yl]carbamate	N F F
223	[3-(1H-tetrazol-1-yl)phenyl]methyl [4- (trifluoromethyl)pyridin-2-yl]carbamate	N N F F F

Table 3		
Entry	Name	Structure
224	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-2- yl]phenyl}methyl)urea	H ₃ C ^{-S} CF ₃
225	[3-(2,6-dimethylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₃ C CF ₃
226	{3-[5-(methyloxy)pyridin-3-yl]phenyl}methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O, CH ₃ O CF ₃ CF ₃
227	2,3'-bipyridin-6-ylmethyl-[4-chloro-3- (trifluoromethyl)phenyl]carbamate	N N CI F F F
228	(6-pyrimidin-5-ylpyridin-2-yl)methyl [4- ehloro-3- (trifluoromethyl)phenyl]carbamate	N O N F F

Table 3		
Entry	Name	Structure
229	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-isoquinolin-4-ylphenyl)methyl]urea	O CF ₃
230	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-isoquinolin-4-ylphenyl)methyl]urea	N N CF ₃
231	[6-(1H-tetrazol-1-yl)pyridin-2-yl]methyl [4-(trifluoromethyl)pyridin-2-yl]carbamate	N O N F F
232	[3-(1H-pyrazol-4-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	O N F F F
233	[4-(1H-pyrazol-4-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	HN _N F _F

- 28. (previously presented) A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
- 29. (cancelled)
- (withdrawn from consideration) A method for modulating the *in-vivo* activity of a kinase, 30. the method comprising administering to a subject an effective amount of the compound according to -claim 1 or a compound selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1acetamide, N-[4-(phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy} acetamide, N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4-dimethylphenyl)-2-{[3-N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1acetamide, (1H-tetrazol-1-yl)phenyl]oxy} N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy}acetamide, acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]ox tetrazol-1-yl)phenyl] oxy}-N-(2,4,6-trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{[3-(1Htetrazol-1-vl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[2acetamide, (methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-chloro-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1vl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1-N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, yl)phenyl]oxy}-N-[2-(trifluoro-methyl)phenyl] acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, methyl 4-[({[3-(1H-tetrazol-1-N-[3-(trifluoromethyl) phenyl] yl)phenyl]oxy}acetyl)amino] benzoate, ethyl 4-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] N-[3benzoate, 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] benzoic acid,

(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide, N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and N-(4-acetylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide.

- 31. (withdrawn from consideration) The method according to claim 30, wherein the kinase is c-Kit.
- 32. (withdrawn from consideration) The method according to claim 31, wherein modulating the *in vivo* activity of c-Kit comprises inhibition of c-Kit.
- (withdrawn from consideration) A method of treating diseases or disorders associated 33. with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in claim 1 or a compound, or a pharmaceutical composition comprising said compound, selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1acetamide, N-[4-(phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenylloxy} acetamide, N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4-dimethylphenyl)-2-{[3-N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1acetamide, (1H-tetrazol-1-yl)phenyl]oxy} N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenylloxy}acetamide, acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]ox tetrazol-1-yl)phenyl]oxy}-N-(2,4,6-trimethylphenyl) acetamide, N-(2-ethyl-phenyl)-2-{[3-(1Htetrazol-1-yl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2acetamide, (methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2-N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, yl)phenyl]oxy} acetamide, N-[2,4-bis(methyl-oxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}

N-[4-(dimethylamino)-phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, acetamide. acetamide, N-(4-chloro-3-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} tetrazol-1-yl)phenyl]oxy} acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} tetrazol-1-yl)phenyl]oxy}-N-[2-(trifluoro-methyl)phenyl] acetamide, 2-{[3-(1H-tetrazol-1yl)phenyl]oxy}-N-[3-(trifluoromethyl) phenyl] acetamide, methyl 4-[({[3-(1H-tetrazol-1yl)phenyl]oxy}acetyl)amino] benzoate, ethyl 4-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy} acetyl) amino] benzoic acid, N-[3benzoate, (methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-vl)phenyl]oxy} acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-vl)phenyl]oxy} tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4triazol-4-yl)phenyl]oxy} acetamide, N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and N-(4acetylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide.

(withdrawn from consideration) A method of screening for modulators of c-Kit, the 34. method comprising combining the compound according to claim 1 or a compound selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-N-(2,3-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide. yl)phenyl]oxy} acetamide, N-(2,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(3,5-dimethylphenyl)-2-{[3acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-(1H-tetrazol-1-yl)phenyl]oxy} 2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-(2,4,6yl)phenyl]oxy}acetamide, trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl)-2-{[3-N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-[2-(ethyloxy)

N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy}acetamide, acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3-dichlorophenyl)acetamide, N-(4-chloro-3-methylphenyl)-2-{[3-(1H-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1tetrazol-1-yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1-N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, yl)phenyl]oxy}-N-[2-(trifluoro-methyl)phenyl] acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, methyl 4-[({[3-(1H-tetrazol-1-N-[3-(trifluoromethyl) phenyl yl)phenyl]oxy}acetyl)amino] benzoate, ethyl 4-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] benzoic acid. N-[3benzoate, (methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]-2-{[3-(1Htetrazol-1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4triazol-4-yl)phenyl]oxy} acetamide, N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and N-(4acetylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and at least one candidate agent and determining the effect of the candidate agent on c-Kit activity.

(withdrawn from consideration) A method of inhibiting proliferative activity in a cell, the 35. method comprising administering an effective amount of a composition comprising the compound according to claim 1 or a compound selected from N-naphthalen-1-yl-2-{[3-(1Hacetamide, N-[4-(phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1tetrazol-1-yl)phenyl]oxy} N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy} acetamide, acetamide, N-(2,3-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5-dimethylphenyl)-2-{[3-N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-(2,4,6trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-N-[2-(ethyloxy) phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenylloxy}acetamide, acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3-dichlorophenyl)-N-(4-chloro-3-methylphenyl)-2-{[3-(1Hacetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1tetrazol-1-yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1yl)phenyl]oxy}-N-[2-(trifluoro-methyl)phenyl] acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, methyl 4-[({[3-(1H-tetrazol-1-N-[3-(trifluoromethyl) phenyl yl)phenyl]oxy}acetyl)amino] benzoate, ethyl 4-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] benzoic acid, N-[3benzoate, (methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]-2-{[3-(1Htetrazol-1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4triazol-4-yl)phenyl]oxy} acetamide, N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and N-(4acetylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, to a cell or a plurality of cells.